BFAD hereby confirms the policy not to require patent clearance for the registration of drug products.  Hence, all drug establishments are advised to exercise vigilance in avoiding infringement of patents and trade marks.

This policy, however, does not preclude any drug establishment from filing a petition or request for cancellation of a drug product registration on valid grounds or in cases of infringement, as the case may be.

Adopted: 28 July 1992